Germline Duplication Detection for Myeloproliferative Neoplasm Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable diagnostic marker for identifying genetic predisposition to myeloproliferative neoplasms (MPNs) and predicting their progression into worse diseases like acute myeloid leukemia, with no major predisposing gene identified for familial MPNs.
Innovation Solution
Identification of a 700 kb germline duplication that predisposes patients to MPNs, particularly essential thrombocythemia, with overexpression of ATG2B and GSKIP genes cooperating with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype, and a method for detecting this duplication to diagnose predisposition and predict disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then no reliable diagnostic marker is available, but this results in inability to identify genetic predisposition to MPNs
Solution Approach 1:
The patent performs preliminary identification of the 700 kb germline duplication and its associated genes (ATG2B, GSKIP, TCL1A) before clinical diagnosis. By establishing this genetic marker in advance through genomic analysis of familial MPN cases, the system enables early detection and risk stratification of patients who may develop MPNs, transforming the diagnostic approach from reactive to proactive.
2Adaptability or versatility
If no major predisposing gene is identified for familial MPNs, then genetic counseling and early intervention are limited, but this results in inability to predict disease progression
Solution Approach 1:
The patent segments the complex genetic landscape of MPNs by identifying specific genes within the 700 kb duplication region (ATG2B, GSKIP, TCL1A) that contribute to disease risk. This segmentation allows for targeted genetic testing and counseling, enabling clinicians to assess individual risk factors and predict disease progression based on the presence and expression levels of specific genes rather than treating MPN genetics as a monolithic problem.
Data Source
AI summary
The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that proposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF), secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL, and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis, a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.